Novo Nordisk A/S (NYSE:NVO) is a top affordable growth stock. UBS maintains a Hold rating with a price target of DKK340.00. Operating profit grew 25% in Danish kroner and 29% at constant exchange rates to DKK 72.2 billion in the first half of 2021. Sales in US and International Operations also saw significant growth.

Novo Nordisk A/S (NYSE:NVO) focuses on diabetes care, with business segments in biopharmaceuticals and diabetes/obesity care. The company develops, manufactures, and markets pharmaceutical products, including GLP-1, insulin, and protein-related products. While NVO shows investment potential, other AI stocks may offer greater upside and less risk.

For more investing insights, check out reports on the best short-term AI stock, stocks that could double in three years, and hidden AI stocks to buy now. Novo Nordisk A/S (NYSE:NVO) is a key player in the global healthcare industry, specializing in diabetes care and providing innovative pharmaceutical solutions.

Read more at Yahoo Finance: UBS Maintains a Hold on Novo Nordisk (NVO)